Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Axitinib Poised To Join Pfizer's RCC Drug Portfolio In 2012

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer's second generation VEGF inhibitor axitinib for advanced renal cell carcinoma has been granted a standard, 10-month review by FDA.

You may also be interested in...



Pfizer’s Inlyta Shows Greater Efficacy In Subpopulation; Will It Be Enough For ODAC And FDA?

Pfizer's Inlyta (axitinib), proposed to treat patients with advanced renal cell carcinoma, seems to work best with patients who have undergone cytokine treatment.

Pfizer Touts Bosutinib Advantages, Debuts Hedgehog Inhibitor At ASH

Among its presentations at the American Society of Hematology meeting, Pfizer debuted Hedgehog Smoothen inhibitor PF-04449913, showing off encouraging Phase I monotherapy data in highly refractory patients. The drug would pair nicely with late-stage bosutinib to hit chronic myelogenous leukemia in two ways: through stem cells and through mature cells, Pfizer’s Rothenberg said.

Astellas Pays $125MM Up-Front To Share Rights To AVEO's Tivozanib

In a worldwide deal excluding Asia, the two companies will split both revenues and development costs 50/50 in North America and Europe.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072432

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel